Role of Inflammation and Its Mediators in Acute Ischemic Stroke

1.

Wang, X. (2005). Investigational anti-inflammatory agents for the treatment of ischemic brain injury. Expert Opinion on Investigational Drugs, 14, 393–409.PubMed

2.

Barone, F. C., & Feuerstein, G. Z. (1999). Inflammatory mediators and stroke: new opportunities for novel therapeutics. Journal of Cerebral Blood Flow and Metabolism, 19, 819–834.PubMed

3.

Chamorro, A., & Hallenbeck, J. (2006). The harms and benefits of inflammatory and immune responses in vascular disease. Stroke, 37, 291–293.PubMed

4.

Samson, Y., Lapergue, B., & Hosseini, H. (2005). Inflammation and ischaemic stroke: current status and future perspectives. Reviews Neurology (Paris), 161, 1177–1182.

5.

Yilmaz, G., & Granger, D. N. (2008). Cell adhesion molecules and ischemic stroke. Neurological Research, 30, 783–793.PubMed

6.

Emsley, H. C., & Hopkins, S. J. (2008). Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurology, 7, 341–353.PubMed

7.

McColl, B. W., Allan, S. M., & Rothwell, N. J. (2009). Systemic infection, inflammation and acute ischemic stroke. Neuroscience, 158, 1049–1061.PubMed

8.

Jin, R., Yang, G., & Li, G. (2010). Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. Journal of Leukocyte Biology, 87, 779–89.PubMed

9.

Iadecola, C., & Anrather, J. (2011). The immunology of stroke: from mechanisms to translation. Nature Medicine, 17, 796–808.PubMed

10.

Hallenbeck, J. M. (1996). Significance of the inflammatory response in brain ischemia. Acta Neurochirurgica. Supplement, 66, 27–31.PubMed

11.

Chopp, M., Li, Y., Jiang, N., Zhang, R. L., & Prostak, J. (1996). Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. Journal of Cerebral Blood Flow and Metabolism, 16, 578–584.PubMed

12.

Connolly, E. S., Jr., Winfree, C. J., Prestigiacomo, C. J., Kim, S. C., Choudhri, T. F., Hoh, B. L., et al. (1997). Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circulation Research, 81, 304–310.PubMed

13.

Garau, A., Bertini, R., Colotta, F., Casilli, F., Bigini, P., Cagnotto, A., et al. (2005). Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine, 30, 125–131.PubMed

14.

Yenari, M. A., Kunis, D., Sun, G. H., Onley, D., Watson, L., Turner, S., et al. (1998). Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Experimental Neurology, 153, 223–233.PubMed

15.

Zheng, Z., & Yenari, M. A. (2004). Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurological Research, 26, 884–892.PubMed

16.

Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Lysko, P. G., et al. (1997). Tumor necrosis factor-α: a mediator of focal ischemic brain injury. Stroke, 28, 1233–1244.PubMed

17.

Rothwell, N., Allan, S., & Toulmond, S. (1997). The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. Journal of Clinical Investigation, 100, 2648–2652.PubMed

18.

Felger, J. C., Abe, T., Kaunzner, U. W., Gottfried-Blackmore, A., Gal-Toth, J., McEwen, B. S., et al. (2010). Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain, Behavior, and Immunity, 24, 724–737.PubMed

19.

Tanaka, R., Komine-Kobayashi, M., Mochizuki, H., Yamada, M., Furuya, T., Migita, M., et al. (2003). Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience, 117, 531–539.PubMed

20.

Konsman, J. P., Drukarch, B., & Van Dam, A. M. (2007). (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clinical Science (London, England), 112, 1–25.

21.

Shigematsu, T., Wolf, R. E., & Granger, D. N. (2002). T-lymphocytes modulate the microvascular and inflammatory responses to intestinal ischemia–reperfusion. Microcirculation, 9, 99–109.PubMed

22.

Zwacka, R. M., Zhang, Y., Halldorson, J., Schlossberg, H., Dudus, L., & Engelhardt, J. F. (1997). CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. Journal of Clinical Investigation, 100, 279–289.PubMed

23.

Yilmaz, G., Arumugam, T. V., Stokes, K. Y., & Granger, D. N. (2006). Role of T lymphocytes and interferon-γ in ischemic stroke. Circulation, 113, 2105–2112.PubMed

24.

Kreutzberg, G. W. (1996). Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences, 19, 312–318.PubMed

25.

Thomas, W. E. (1992). Brain macrophages: evaluation of microglia and their functions. Brain Research, 17, 61–74.PubMed

26.

Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y. C., & Kriz, J. (2007). Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. Journal of Neuroscience, 27, 2596–2605.PubMed

27.

Lai, A. Y., & Todd, K. G. (2006). Microglia in cerebral ischemia: molecular actions and interactions. Canadian Journal of Physiology and Pharmacology, 84, 49–59.PubMed

28.

Denes, A., Vidyasagar, R., Feng, J., Narvainen, J., McColl, B. W., Kauppi-nen, R. A., et al. (2007). Proliferating resident microglia after focal cerebral ischaemia in mice. Journal of Cerebral Blood Flow and Metabolism, 27, 1941–1953.PubMed

29.

George, B., Robin, E., White, Y. O., Lijun, X., & Giffard, G. R. (2011). Astrocytes: targets for neuroprotection in stroke. Central Nervous System Agents in Medicinal Chemistry, 11, 164–173.

30.

Nowicka, D., Rogozinska, K., Aleksy, M., Witte, O. W., & Skangiel-Kramska, J. (2008). Spatiotemporal dynamics of astroglial and microglial responses after photothrombotic stroke in the rat brain. Acta Neurobiologiae Experimentalis (Wars), 68, 155–168.

31.

Zhu, Y., Roth-Eichhorn, S., Braun, N., Culmsee, C., Rami, A., & Krieglstein, J. (2000). The expression of transforming growth factor-beta1 (TGF-beta1) in hippocampal neurons: a temporary upregulated protein level after transient forebrain ischemia in the rat. Brain Research, 866, 286–298.PubMed

32.

Benveniste, E. N. (1998). Cytokine actions in the central nervous system. Cytokine & Growth Factor Reviews, 9, 259–275.

33.

Che, X., Ye, W., Panga, L., Wu, D. C., & Yang, G. Y. (2001). Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Research, 902, 171–177.PubMed

34.

Dong, Y., & Benveniste, E. N. (2001). Immune function of astrocytes. Glia, 36, 180–190.PubMed

35.

Wang, W., Redecker, C., Yu, Z. Y., Xie, M. J., Tian, D. S., Zhang, L., et al. (2008). Rat focal cerebral ischemia induced astrocyte proliferation and delayed neuronal death are attenuated by cyclin-dependent kinase inhibition. Journal of Clinical Neuroscience, 15, 278–285.PubMed

36.

Sharif, A., Legendre, P., Prevot, V., Allet, C., Romao, L., Studler, J. M., et al. (2007). Transforming growth factor alpha promotes sequential conversion of mature astrocytes into neural progenitors and stem cells. Oncogene, 26, 2695–2706.PubMed

37.

Justicia, C., Perez-Asensio, F. J., Burguete, M. C., Salom, J. B., & Planas, A. M. (2001). Administration of transforming growth factor-alpha reduces infarct volume after transient focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism, 21, 1097–1104.PubMed

38.

Meistrell, M. E., 3rd, Botchkina, G. I., Wang, H., Di Santo, E., Cockroft, K. M., Bloom, O., et al. (1997). Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock, 8, 341–348.PubMed

39.

Barger, S. W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J., & Mattson, M. P. (1996). Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca²⁺ accumulation. Proceedings of the National Academy of Sciences of the United States of America, 92, 9328–9332.

40.

Lambertsen, K. L., Clausen, B. H., Babcock, A. A., Gregersen, R., Fenger, C., Nielsen, H. H., et al. (2009). Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. Journal of Neuroscience, 29, 1319–1330.PubMed

41.

Boutin, H., LeFeuvre, R. A., Horai, R., Asano, M., Iwakura, Y., & Rothwell, N. J. (2001). Role of IL-1alpha and IL-1beta in ischemic brain damage. Journal of Neuroscience, 21, 5528–5534.PubMed

42.

Yamasaki, Y., Matsuura, N., Shozuhara, H., Onodera, H., Itoyama, Y., & Kogure, K. (1995). Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke, 26, 676–680.PubMed

43.

Loddick, S. A., Turnbull, A. V., & Rothwell, N. J. (1998). Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism, 18, 176–179.PubMed

44.

Stamatovic, S. M., Shakui, P., Keep, R. F., Moore, B. B., Kunkel, S. L., Van, R. N., et al. (2005). Monocyte chemoattractant protein-1 regulation of blood–brain barrier permeability. Journal of Cerebral Blood Flow and Metabolism, 25, 593–606.PubMed

45.

Soriano, S. G., Amaravadi, L. S., Wang, Y. F., Zhou, H., Yu, G. X., Tonra, J. R., et al. (2002). Mice deficient in fractalkine are less susceptible to cerebral ischemia–reperfusion injury. Journal of Neuroimmunology, 125, 59–65.PubMed

46.

Spera, P. A., Ellison, J. A., Feuerstein, G. Z., & Barone, F. C. (1998). IL-10 reduces rat brain injury following focal stroke. Neuroscience Letters, 251, 189–192.PubMed

47.

Ooboshi, H., Ibayashi, S., Shichita, T., Kumai, Y., Takada, J., & Ago, T. (2005). Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation, 111, 913–919.PubMed

48.

Pang, L., Ye, W., Che, X. M., Roessler, B. J., Betz, A. L., & Yang, G. Y. (2001). Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-ss1 expression. Stroke, 32, 544–552.PubMed

49.

Ruocco, A., Nicole, O., Docagne, F., Ali, C., Chazalviel, L., Komesli, S., et al. (1999). A transforming growth factor-b antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. Journal of Cerebral Blood Flow and Metabolism, 19, 1345–1353.PubMed

50.

Zhang, Y., Wei, X., Liu, L., Liu, S., Wang, Z., Zhang, B., et al. (2012). TIPE2, a novel regulator of immunity, protects against experimental stroke. Journal of Biological Chemistry, 287, 32546–32555.PubMed

51.

Kooijman, R., Sarre, S., Michotte, Y., & Keyser, D. J. (2009). Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke, 404, e83–88.

52.

Denti, L., Annoni, V., Cattadori, E., Salvagnini, M. A., Visioli, S., & Merli, M. F. (2004). Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. American Journal of Medicine, 117, 312–317.PubMed

53.

Liu, T., Clark, R. K., McDonnell, P. C., Young, P. R., White, R. F., & Barone, F. C. (1994). Tumor necrosis factor-α expression in ischemic neurons. Stroke, 25, 1481–1488.PubMed

54.

Wang, X., Yue, T. L., Barone, F. C., White, R. F., Gagnon, R. C., & Feuerstein, G. Z. (1994). Concomitant cortical expression of TNF-α and IL-1 α mRNAs follows early response gene expression in transient focal ischemia. Molecular and Chemical Neuropathology, 23, 103–114.PubMed

55.

Murakami, Y., Saito, K., Hara, A., Zhu, Y., Sudo, K., Niwa, M., et al. (2005). Increases in tumor necrosis factor-alpha following transient global cerebral ischemia do not contribute to neuron death in mouse hippocampus. Journal of Neurochemistry, 93, 1616–1622.PubMed

56.

Offner, H., Subramanian, S., Parker, S. M., Afentoulis, M. E., Vandenbark, A. A., & Hurn, P. D. (2006). Experimental stroke induces massive, rapid activation of the peripheral immune system. Journal of Cerebral Blood Flow and Metabolism, 26, 654–665.PubMed

57.

Hallenbeck, J. M. (2002). The many faces of tumor necrosis factor in stroke. Nature Medicine, 8, 1363–1368.PubMed

58.

Ginis, I., Jaiswal, R., Klimanis, D., Liu, J., Greenspon, J., & Hallenbeck, J. M. (2002). TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor. Journal of Cerebral Blood Flow and Metabolism, 22, 142–152.PubMed

59.

Alikhani, M., Alikhani, Z., Raptis, M., & Graves, D. T. J. (2004). TNF-alpha in vivo stimulates apoptosis in fibroblasts through caspase-8 activation and modulates the expression of pro-apoptotic genes. Cell Physiology, 201, 341–348.

60.

Plumpe, J., Malek, N. K., Bock, C. T., Rakemann, T., Manns, M. P., & Trautwein, C. (2000). NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. American Journal of Physiology—Gastrointestinal and Liver Physiology, 278, 173–183.

61.

Zeng, L., Liu, J., Wang, Y., Wang, L., Weng, S., Chen, S., et al. (2012). Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. European Neurology, 69(2), 68–75.PubMed

62.

Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., & Kostura, M. J. (1992). A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature, 356, 768–774.PubMed

63.

Dinarello, C. A. (1996). Biologic basis for interleukin-1 in disease. Blood, 15, 2095–2147.

64.

Black, R. A., Kronheim, S. R., & Sleath, P. R. (1989). Activation of interleukin-1β by a co-induced protease. FEBS Letters, 247, 386–390.PubMed

65.

Schonbeck, V., Mach, F., & Libby, P. (1998). Generation of biologically active IL-1β by matrix metalloproteinase a novel caspase-1 independent pathway of IL-1β processing. Journal of Immunology, 161, 3340–3346.

66.

Dinarello, C. A., & Wolff, S. M. (1993). The role of interleukin-1 in disease. New England Journal of Medicine, 328, 106–113.PubMed

67.

Bankers-Fulbright, J. L., Kalli, K. R., & McLean, D. J. (1996). IL-1 signal transduction. Life Sciences, 59, 61–83.PubMed

68.

Rothwell, N. J., & Luheshi, G. N. (2000). Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends in Neurosciences, 23, 618–625.PubMed

69.

Koga, S., Ogawa, S., Kuwabara, K., Brett, J., Leavy, J. A., & Ryan, J. (1992). Synthesis and release of interleukin 1 by reoxygenated human mononuclear phagocytes. Journal of Clinical Investigation, 90, 1007–1015.PubMed

70.

Basu, A., Lazovic, J., Krady, J. K., Mauger, D. T., Rothstein, R. P., Smith, M. B., et al. (2005). Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. Journal of Cerebral Blood Flow and Metabolism, 25, 17–29.PubMed

71.

Herrmann, O., Tarabin, V., Suzuki, S., Attigah, N., Coserea, I., & Schneider, A. (2003). Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 23, 406–415.PubMed

72.

Waje-Andreassen, U., Kråkenes, J., Ulvestad, E., Thomassen, L., Myhr, K. M., Aarseth, J., et al. (2005). IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurologica Scandinavica, 111, 360–365.PubMed

73.

Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (1813). The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta, 2011, 878–888.

74.

Connolly, E. S. J., Winfree, C. J., Springer, T. A., Naka, Y., Liao, H., & Yan, S. D. (1996). Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. Journal of Clinical Investigation, 97, 209–16.PubMed

75.

Moore, K. L., Eaton, S. F., Lyons, D. E., Lichenstein, H. S., Cummings, R. D., & McEver, R. P. (1994). The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine. Journal of Biological Chemistry, 269, 23318–23327.PubMed

76.

Stenberg, P. E., Shuman, M. A., Levine, S. P., & Bainton, D. F. (1984). Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. Journal of Cell Biology, 98, 748–760.PubMed

77.

Bargatze, R. F., Kurk, S., Butcher, E. C., & Jutila, M. A. (1994). Neutrophils roll on adherent neutrophils bound to cytokine-induced endothelial cells via L-selectin on the rolling cells. Journal of Experimental Medicine, 180, 1785–1792.PubMed

78.

Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O., & Wagner, D. D. (1993). Leukocyte rolling and extravasation are severely compromised in P-selectin deficient mice. Cell, 74, 541–554.PubMed

79.

Huang, J., Kim, L. J., Mealey, R., Marsh, H. C., Zhang, Y., Tenner, A. J., et al. (1999). Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science, 285, 595–599.PubMed

80.

Huang, J., Choudhri, T. F., Winfree, C. J., McTaggart, R. A., Kiss, S., Mocco, J., et al. (2000). Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke, 31, 3047–3053.PubMed

81.

Mocco, J., Choudhri, T., Huang, J., Harfeldt, E., Efros, L., Klingbeil, C., et al. (2002). HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circulation Research, 91, 907–914.PubMed

82.

Lehmberg, J., Beck, J., Baethmann, A., & Uhl, E. (2006). Effect of P-selectin inhibition on leukocyte endothelium interaction and survival after global cerebral ischemia. Journal of Neurology, 253, 357–363.PubMed

83.

Cha, J. K., Jeong, M. H., Kim, E. K., Lim, Y. J., Ha, B. R., & Kim, S. H. (2002). Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke. Journal of Korean Medical Science, 17, 811–816.PubMed

84.

Zhao, D. X., Feng, J., Cong, S. Y., & Zhang, W. (2012). Association of E-selectin gene polymorphisms with ischemic stroke in a Chinese Han population. Journal of Neuroscience Research, 90, 1782–1787.PubMed

85.

Kaba, N. K., Schultz, J., Law, F. Y., Lefort, C. T., Martel-Gallegos, G., Kim, M., et al. (2008). Inhibition of Na⁺/H⁺ exchanger enhances low pH-induced L-selectin shedding and beta2-integrin surface expression in human neutrophils. American Journal of Physiology. Cell Physiology, 295, C1454–1463.PubMed

86.

Springer, T. A. (1990). Adhesion receptors of the immune system. Nature, 346, 425.PubMed

87.

Gahmberg, C. G. M., Tolvanen, P., & Kotovuori. (1997). Leukocyte adhesion: structure and function of human leukocyte β2-integrins and their cellular ligands. European Journal of Biochemistry, 245, 215–232.PubMed

88.

Diacovo, T. G., de Fougerolles, A. R., Bainton, D. F., & Springer, T. A. (1994). A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. Journal of Clinical Investigation, 94, 1243–1251.PubMed

89.

Zhang, R. L., Chopp, M., Chen, H., & Garcia, J. H. (1994). Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. Journal of Neurological Sciences, 125, 3–10.

90.

Kanemoto, Y., Nakase, H., Akita, N., & Sakaki, T. (2002). Effects of anti-intercellular adhesion molecule-1 antibody on reperfusion injury induced by late reperfusion in the rat middle cerebral artery occlusion model. Neurosurgery, 51, 1034–1041.PubMed

91.

Kitagawa, K., Matsumoto, M., Mabuchi, T., Yagita, Y., Ohtsuki, T., Hori, M., et al. (1998). Deficiency of intercellular adhesion molecule 1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 18, 1336–1345.PubMed

92.

Khan, M., Jatana, M., Elango, C., Singh, P. A., Singh, A. K., & Singh, I. (2006). Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke. Nitric Oxide, 15, 114–124.PubMed

93.

Vemuganti, R., Dempsey, R. J., & Bowen, K. K. (2004). Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke, 35, 179–184.PubMed

94.

Shyu, K. G., Chang, H., & Lin, C. C. (1997). Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke. Journal of Neurology, 244, 90–93.PubMed

95.

Lindsberg, P. J., Carpen, O., Paetau, A., Karjalainen-Lindsberg, M. L., & Kaste, M. (1996). Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation, 94, 939–945.PubMed

96.

Enlimomab, A. S. T. (2001). Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology, 57, 1428–1434.

97.

Vuorte, J., Lindsberg, P. J., Kaste, M., Meri, S., Jansson, S. E., Rothlein, R., et al. (1999). Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. Journal of Immunology, 162, 2353–2357.

98.

Zhang, L. H., & Wei, E. Q. (2003). Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacologica Sinica, 24, 1241–1247.PubMed

99.

Justicia, C., Martin, A., Rojas, S., Gironella, M., Cervera, A., Panes, J., et al. (2006). Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. Journal of Cerebral Blood Flow and Metabolism, 26, 421–432.PubMed

100.

Bajetto, A., Bonavia, R., Barbero, S., Florio, T., & Schettini, G. (2001). Chemokines and their receptors in the central nervous system. Frontiers in Neuroendocrinology, 22, 147–184.PubMed

101.

Chen, Y., Hallenbeck, J. M., Ruetzler, C., Bol, D., Thomas, K., Berman, N. E., et al. (2003). Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. Journal of Cerebral Blood Flow and Metabolism, 23, 748–755.PubMed

102.

Lambertsen, K. L., Biber, K., & Finsen, B. (2012). Inflammatory cytokines in experimental and human stroke. Journal of Cerebral Blood Flow and Metabolism, 32, 1677–1698.PubMed

103.

Wang, L., Li, Y., Chen, X., Chen, J., Gautam, S. C., Xu, Y., et al. (2002). MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology, 7, 113–117.PubMed

104.

Wang, L., Li, Y., Chen, J., Gautam, S. C., Zhang, Z., Lu, M., et al. (2002). Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Experimental Hematology, 30, 831–836.PubMed

105.

Lee, S. R., Kim, H. Y., Rogowska, J., Zhao, B. Q., Bhide, P., Parent, J. M., et al. (2006). Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. Journal of Neuroscience, 26, 3491–3495.PubMed

106.

Zhao, B. Q., Wang, S., Kim, H. Y., Storrie, H., Rosen, B. R., Mooney, D. J., et al. (2006). Role of matrix metalloproteinases in delayed cortical responses after stroke. Nature Medicine, 12, 441–445.PubMed

107.

Rosenberg, G. A., Navratil, M., Barone, F., & Feuerstein, G. (1996). Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. Journal of Cerebral Blood Flow and Metabolism, 16, 360–366.PubMed

108.

Clark, A. W., Krekoski, C. A., Bou, S. S., Chapman, K. R., & Edwards, D. R. (1997). Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neuroscience Letters, 238, 53–56.PubMed

109.

Castellanos, M., Leira, R., Serena, J., Pumar, J. M., Lizasoain, I., & Castillo, J. (2003). Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke, 34, 40–46.PubMed

110.

Montaner, J., Alvarez-Sabin, J., Molina, C., Angles, A., Abilleira, S., & Arenillas, J. (2001). Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke, 32, 1759–1766.PubMed

111.

Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J. C., Moskowitz, M. A., et al. (2001). Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. Journal of Neuroscience, 21, 7724–32.PubMed

112.

Tarkowski, E., Rosengren, L., Blomstrand, C., Wikkelso, C., Jensen, C., Ekholm, S., et al. (1997). Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clinical and Experimental Immunology, 110, 492–499.PubMed

113.

Pelidou, S. H., Kostulas, N., Matusevicius, D., Kivisakk, P., Kostulas, V., & Link, H. (1999). High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. European Journal of Neurology, 6, 437–442.PubMed

114.

Strle, K., Zhou, J. H., Shen, W. H., Broussard, S. R., Johnson, R. W., Freund, G. G., et al. (2001). Interleukin-10 in the brain. Critical Reviews in Immunology, 21, 427–449.PubMed

115.

Grilli, M., Barbieri, I., Basudev, H., Brusa, R., Casati, C., Lozza, G., et al. (2000). Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. European Journal of Neuroscience, 12, 2265–2272.PubMed

116.

Kim, J. S., Yoon, S. S., Kim, Y. H., & Ryu, J. S. (1996). Serial measurement of interleukin-6, transforming growth factor-beta, and S 100 protein in patients with acute stroke. Stroke, 27, 1553–1557.PubMed

117.

van Exel, E., Gussekloo, J., de Craen, A. J., Bootsma-van, D. W. A., Frolich, M., & Westendorp, R. G. (2002). Inflammation and stroke: the Leiden 85-Plus Study. Stroke, 33, 1135–1138.PubMed

118.

Buckwalter, M., & Wyss-Coray, T. (2004). Modelling neuroinflammatory phenotypes in vivo. Journal of Neuroinflammation, 1, 10.PubMed

119.

Klempt, N. D., Sirimanne, E., Gunn, A. J., Klempt, M., Singh, K., & Williams, C. (1992). Hypoxia–ischemia induces transforming growth factor beta 1 mRNA in the infant rat brain. Molecular Brain Research, 13, 93–101.PubMed

120.

Wienner, C., Gehrmann, J., Lindholm, D., Topper, R., Kreutzberg, G. W., & Hossmann, K. A. (1993). Expression of transforming growth factor-beta1 and interleukin-1 beta mRNA in rat brain following transient fore-brain ischemia. Acta Neuropathologica, 86, 439–46.

121.

Johnston, R. E., Dillon-Carter, O., Freed, W. J., & Borlongan, C. V. (2001). Trophic factor secreting kidney cell lines: in vitro characterization and functional effects following transplantation in ischemic rats. Brain Research, 900, 268–276.PubMed

122.

Sun, H., Gong, S., Carmody, R. J., Hilliard, A., Li, L., Sun, J., et al. (2008). TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell, 133, 415–426.PubMed

123.

Zhang, X., Wang, J., Fan, C., Li, H., Sun, H., Gong, S., et al. (2009). Crystal structure of TIPE2 provides insights into immune homeostasis. Nature Structural and Molecular Biology, 16, 89–90.PubMed

124.

Kooijman, R. (2006). Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine & Growth Factor Reviews, 17, 305–323.

125.

Liu, X. F., Fawcett, J. R., Hanson, L. R., & Frey, W. H. (2004). The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. Journal of Stroke and Cerebrovascular Diseases, 13, 16–23.PubMed

126.

Liu, X. F., Fawcett, J. R., Thorne, R. G., DeFor, T. A., & Frey, W. H. (2001). Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage. Journal of Neurological Sciences, 187, 91–97.

127.

De, S. A., Brouns, R., Uyttenboogaart, M., De, R. S., Moens, M., Wilczak, N., et al. (2011). Insulin-like growth factor I serum levels influence ischemic stroke outcome. Stroke, 42, 2180–2185.

128.

Bsibsi, M., Persoon-Deen, C., Verwer, R. W., Meeuwsen, S., Ravid, R., & Van, N. J. M. (2006). Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia, 53, 688–695.PubMed

129.

Bsibsi, M., Ravid, R., Gveric, D., & Van Noort, J. M. (2002). Broad expression of Toll-like receptors in the human central nervous system. Journal of Neuropathology and Experimental Neurology, 61, 1013–1021.PubMed

130.

Singh, A. K., & Jiang, Y. (2004). How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology, 201, 197–207.PubMed

131.

Jack, C. S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., et al. (2005). TLR signaling tailors innate immune responses in human microglia and astrocytes. Journal of Immunology, 175, 4320–4330.

132.

Marsh, B. J., Williams-Karnesky, R. L., & Stenzel-Poore, M. P. (2009). Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience, 158, 1007–1020.PubMed

133.

Sakata, Y., Dong, J. W., Vallejo, J. G., Huang, C. H., Baker, J. S., Tracey, K. J., et al. (2007). Toll-like receptor 2 modulates left ventricular function following ischemia–reperfusion injury. American Journal of Physiology—Heart and Circulatory Physiology, 292, H503–H509.PubMed

134.

Shigeoka, A. A., Holscher, T. D., King, A. J., Hall, F. W., Kiosses, W. B., Tobias, P. S., et al. (2007). TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. Journal of Immunology, 178, 6252–6258.

135.

Cao, C. X., Yang, Q. W., Lv, F. L., Cui, J., Fu, H. B., & Wang, J. Z. (2007). Reduced cerebral ischemia–reperfusion injury in Toll-like receptor 4 deficient mice. Biochemical and Biophysical Research Communications, 353, 509–514.PubMed

136.

Lehnardt, S., Schott, E., Trimbuch, T., Laubisch, D., Krueger, C., Wulczyn, G., et al. (2008). A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. Journal of Neuroscience, 28, 2320–2331.PubMed

137.

Ziegler, G., Harhausen, D., Schepers, C., Hoffmann, O., Rohr, C., Prinz, V., et al. (2007). TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochemical and Biophysical Research Communications, 359, 574–579.PubMed

138.

Caso, J. R., Pradillo, J. M., Hurtado, O., Lorenzo, P., Moro, M. A., & Lizasoain, I. (2007). Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation, 115, 1599–1608.PubMed

139.

Hua, F., Ma, J., Ha, T., Xia, Y., Kelley, J., Williams, D. L., et al. (2007). Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. Journal of Neuroimmunology, 190, 101–111.PubMed

140.

Kinouchi, H., Sharp, F. R., Hill, M. P., Koistinaho, J., Sagar, S. M., & Chan, P. H. (1993). Induction of 70-kDa heat shock protein and hsp70 mRNA following transient focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism, 13, 105–115.PubMed

141.

Faraco, G., Fossati, S., Bianchi, M. E., Patrone, M., Pedrazzi, M., Sparatore, B., et al. (2007). High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. Journal of Neurochemistry, 103, 590–603.PubMed

142.

Schneider, A., Martin-Villalba, A., Weih, F., Vogel, J., Wirth, T., & Schwaninger, M. (1999). NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nature Medicine, 5, 554–559.PubMed

143.

Liu, H., Xin, L., Chan, B. P. L., Teoh, R., Tang, B. L., & Tan, Y. H. (2002). Interferon beta administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia. Neuroscience Letters, 327, 146–148.PubMed

144.

Veldhuis, W., Derksen, J., Floris, S., Vander, M. P., de Vries, H., Schepers, J., et al. (2003). Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. Journal of Cerebral Blood Flow and Metabolism, 23, 1029–1039.PubMed

145.

Bogoyevitch, M. A., Gillespie-Brown, J., Ketterman, A. J., Fuller, S. J., Ben-Levy, R., Ashworth, A., et al. (1996). Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circulation Research, 79, 162–173.PubMed

146.

Ferrell, J. E. (1996). Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends in Biochemical Sciences, 21, 460–466.PubMed

147.

Davis, R. J. (1993). The mitogen-activated protein kinase signal transduction pathway. Journal of Biological Chemistry, 268, 14553–14556.PubMed

148.

Nithianandarajah-Jones, G. N., Wilm, B., Goldring, C. E., Müller, J., & Cross, M. J. (2012). ERK5: structure, regulation and function. Cellular Signalling, 24, 2187–2196.PubMed

149.

Lewis, T. S., Shapiro, P. S., & Ahn, N. G. (1998). Signal transduction through MAP kinase cascades. Advances in Cancer Research, 74, 49–139.PubMed

150.

Sutton, L. N., Clark, B. J., Norwood, C. R., Woodford, E. J., & Welsh, F. A. (1991). Global cerebral ischemia in piglets under conditions of mild and deep hypothermia. Stroke, 22, 1567–1573.PubMed

151.

Kamme, F., Camp, K., & Wieloch, T. (1995). Biphasic expression of the fos and jun families of transcription factors following transient forebrain ischaemia in the rat. Effect of hypothermia. European Journal of Neuroscience, 7, 2007–2016.PubMed

152.

Wang, Z. Q., Wu, D. C., Huang, F. P., & Yang, G. Y. (2004). Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Research, 996, 55–66.PubMed

153.

Barnes, P. J. (2010). Mechanisms and resistance in glucocorticoid control of inflammation. Journal of Steroid Biochemistry and Molecular Biology, 120, 6–85.

154.

Woo, C. H., Massett, M. P., Shishido, T., Itoh, S., Ding, B., McClain, C., et al. (2006). ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. Journal of Biological Chemistry, 281, 32164–32174.PubMed

155.

Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270, 1326–1331.PubMed

156.

Kawasaki, H., Morooka, T., Shimohama, S., Kimura, J., Hirano, T., Gotoh, Y., et al. (1997). Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. Journal of Biological Chemistry, 272, 18518–18521.PubMed

157.

Guan, Q. H., Pei, D. S., Zong, Y. Y., Xu, T. L., & Zhang, G. Y. (2006). Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways. Neuroscience, 139, 609–627.PubMed

158.

Sawe, N., Steinberg, G., & Zhao, H. (2008). Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. Journal of Neuroscience Research, 86, 1659–1669.PubMed

159.

Benakis, C., Bonny, C., & Hirt, L. (2010). JNK inhibition and inflammation after cerebral ischemia. Brain, Behavior, and Immunity, 24, 800–811.PubMed

160.

Kaminska, B. (2005). MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefits. Biochimica et Biophysica Acta, 1754, 253–262.PubMed

161.

Wang, L. W., Tu, Y. F., Huang, C. C., & Ho, C. J. (2012). JNK signaling is the shared pathway linking neuroinflammation, blood–brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain. Journal of Neuroinflammation, 17, 175.

162.

Barone, F. C., Irving, E. A., & Ray, A. M. (2001). Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Medicinal Research Reviews, 21, 129–145.PubMed

163.

Wang, H., Xu, L., Venkatachalam, S., Trzaskos, J. M., Friedman, S. M., Feuerstein, G. Z., et al. (2001). Differential regulation of IL-1beta and TNF-alpha RNA expression by MEK1 inhibitor after focal cerebral ischemia in mice. Biochemical and Biophysical Research Communications, 286, 869–874.PubMed

164.

Maddahi, A., & Edvinsson, L. (2008). Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neuroscience, 9, 85.PubMed

165.

Alessandrini, A., Namura, S., Moskowitz, M. A., & Bonventre, J. V. (1999). MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America, 96, 12866–12869.PubMed

166.

Wang, X., Wang, H., Xu, L., Rozanski, D. J., Sugawara, T., Chan, P. H., et al. (2003). Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. Journal of Pharmacology and Experimental Therapeutics, 304, 172–178.PubMed

167.

Roux, P. P., & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68, 320–344.PubMed

168.

Han, B. H., & Holtzman, D. M. (2000). BDNF protects the neonatal brain from hypoxic–ischemic injury in vivo via the ERK pathway. Journal of Neuroscience, 20, 5775–5781.PubMed

169.

Wang, R. M., Zhang, Q. G., Li, J., Yang, L. C., Yang, F., & Brann, D. W. (2009). The ERK5-MEF2C transcription factor pathway contributes to anti-apoptotic effect of cerebral ischemia preconditioning in the hippocampal CA1 region of rats. Brain Research, 1255, 32–41.PubMed

170.

Ridder, D. A., & Schwaninger, M. (2009). NF-kappaB signaling in cerebral ischemia. Neuroscience, 158, 995–1006.PubMed

171.

Napetschnig, J., & Wu, H. (2013). Molecular basis of NF-κB signaling. Annual Review of Biophysics, 42, 443–68.PubMed

172.

Khan, M., Sekhon, B., Giri, S., Jatana, M., Gilg, A. G., Ayasolla, K., et al. (2005). S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke. Journal of Cerebral Blood Flow and Metabolism, 25, 177–192.PubMed

173.

Hill, W. D., Hess, D. C., Carroll, J. E., Wakade, C. G., Howard, E. F., Chen, Q., et al. (2001). The NF-kappaB inhibitor diethyldithiocarbamate (DDTC) increases brain cell death in a transient middle cerebral artery occlusion model of ischemia. Brain Research Bulletin, 55, 375–86.PubMed

174.

Smith, C. J., Emsley, H. C., Vail, A., Georgiou, R. F., Rothwell, N. J., Tyrrell, P. J., et al. (2006). Variability of the systemic acute phase response after ischemic stroke. Journal of Neurological Sciences, 251, 77–81.

175.

Palasik, W., Fiszer, U., Lechowicz, W., Czartoryska, B., Krzesiewicz, M., & Lugowska, A. (2005). Assessment of relations between clinical outcome of ischemic stroke and activity of inflammatory processes in the acute phase based on examination of selected parameters. European Neurology, 53, 188–193.PubMed

176.

McColl, B. W., Rothwell, N. J., & Allan, S. M. (2008). Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. Journal of Neuroscience, 28, 9451–9462.PubMed

177.

Dandona, P., Aljada, A., & Bandyopadhyay, A. (2004). Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 25, 4–7.PubMed

178.

Hansson, G. K., & Libby, P. (2006). The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology, 6, 508–519.PubMed

179.

McGill, J. K., Gallagher, L., Carswell, H. V., Irving, E. A., Dominiczak, A. F., & Macrae, I. M. (2005). Impaired functional recovery after stroke in the stroke-prone spontaneously hypertensive rat. Stroke, 36, 135–141.PubMed

180.

Tureyen, K., Kapadia, R., Bowen, K. K., Satriotomo, I., Liang, J., Feinstein, D. L., et al. (2007). Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. Journal of Neurochemistry, 101, 41–56.PubMed

181.

Warlow, C., Sudlow, C., Dennis, M., Wardlaw, J., & Sandercock, P. (2003). Stroke. Lancet, 362, 1211–1224.PubMed

182.

Krakauer, J. W. (2007). The complex dynamics of stroke onset and progression. Current Opinion in Neurology, 20, 47–50.PubMed

183.

Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., & Corasaniti, M. T. (2009). Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS Journal, 276, 13–26.PubMed

184.

Kriz, J. (2006). Inflammation in ischemic brain injury: timing is important. Critical Reviews in Neurobiology, 18, 145–157.PubMed

185.

Ruehl, M. L., Orozco, J. A., Stoker, M. B., McDonagh, P. F., Coull, B. M., & Ritter, L. S. (2002). Protective effects of inhibiting both blood and vascular selectins after stroke and reperfusion. Neurological Research, 24, 226–232.PubMed

186.

Zhang, R. L., Chopp, M., Jiang, N., Tang, W. X., Prostak, J., Manning, A. M., et al. (1995). Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke, 26, 1438–1442.PubMed

187.

Chopp, M., Zhang, R. L., Chen, H., Li, Y., Jiang, N., & Rusche, J. R. (1994). Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke, 25, 869–875.PubMed

188.

Ma, M., Ma, Y., Yi, X., Guo, R., Zhu, W., Fan, X., et al. (2008). Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neuroscience, 10, 117.

189.

Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006). TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 24, 179–189.PubMed

190.

Taylor, A., Verhagen, J., Blaser, K., Akdis, M., & Akdis, C. A. (2006). Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology, 117, 433–442.PubMed

191.

Emsley, H. C., Smith, C. J., Georgiou, R. F., Vail, A., Hopkins, S. J., Rothwell, N. J., et al. (2005). Acute stroke investigators: a randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1366–1372.PubMed

192.

Krams, M., Lees, K. R., Hacke, W., Grieve, A. P., Orgogozo, J. M., & Ford, G. A. (2003). ASTIN Study Investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose–response study of UK-279,276 in acute ischemic stroke. Stroke, 34, 2543–2548.PubMed

193.

Becker, K. J. (2002). Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Current Medical Research and Opinion, 18, s18–22.PubMed

194.

Danton, G. H., & Dietrich, W. D. (2003). Inflammatory mechanisms after ischemia and stroke. Neuropathology and Experimental Neurology, 62, 127–136.

195.

Minnerup, J., Sutherland, B. A., Buchan, A. M., & Kleinschnitz, C. (2012). Neuroprotection for stroke: current status and future perspectives. International Journal of Molecular Sciences, 13, 11753–11772.PubMed

196.

Mergenthaler, P., & Meisel, A. (2012). Do stroke models model stroke? Disease Models & Mechanisms, 5, 718–725.

197.

Zaremba, J., & Losy, J. (2001). Early TNF-α levels correlate with ischemic stroke severity. Acta Neurologica Scandinavica, 104, 288–295.PubMed

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Role of Inflammation and Its Mediators in Acute Ischemic Stroke

Abstract

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Diagnosing and Characterizing Coronary Artery Disease in Women: Developments in Noninvasive and Invasive Imaging Techniques

No-Reflow Reversibility: A Study Based on Serial Assessment of Multiple Biomarkers

Myocardial Infarction in Sickle Cell Disease: Use of Translational Imaging to Diagnose an Under-Recognized Problem

Coronary Flow Reserve from Mouse to Man—from Mechanistic Understanding to Future Interventions